BARRY MASSIE, M.D.; E. PAUL MacCARTHY, M.D.; K. B. RAMANATHAN, M.D.; ROBERT. J. WEISS, M.D.; MERRILL ANDERSON, M.D.; BRUCE A. EIDELSON, M.D.; DUSTAN G. LABRECHE, Pharm.D.; JULIO F. TUBAU, M.D.; DIOSDADO ULEP, M.D.; DAVID BARTELS, Pharm.D.
We compared the safety and efficacy of diltiazem and propranolol, and examined demographic factors influencing responses to these agents. One hundred ninety-six patients with supine diastolic blood pressures of 95 to 114 mm Hg were treated with propranolol (80 to 240 mg twice a day) or a sustained-release preparation of diltiazem (60 to 180 mg twice a day) in a double-blind, randomized, parallel group protocol for 6 months. Hydrochlorothiazide was added for patients not achieving the treatment goal. Both agents produced nearly identical and highly significant (p < 0.001) reductions in supine blood pressure. There were no significant differences at the end of the optional combination therapy phase, although additional reduction with hydrochlorothiazide was slightly greater in the propranolol group. Blood pressure responses in relation to age, gender, race, and smoking history showed that diltiazem produced greater changes in older subjects and women, whereas propranolol was less effective in blacks. However, these differences were not critical.
MASSIE B, MacCARTHY EP, RAMANATHAN KB, WEISS RJ, ANDERSON M, EIDELSON BA, et al. Diltiazem and Propranolol in Mild to Moderate Essential Hypertension as Monotherapy or with Hydrochlorothiazide. Ann Intern Med. ;107:150–157. doi: 10.7326/0003-4819-107-2-150
Download citation file:
Published: Ann Intern Med. 1987;107(2):150-157.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use